U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06864026) titled 'A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice' on March 03.
Brief Summary: The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Psoriatic Arthritis
Overweight or Obesity
Intervention:
DRUG: Tirze...